TX-WEA
27.10.2021 10:34:07 CEST | Business Wire | Press release
The Women’s Entrepreneurship Accelerator (WEA), a strategic multi-partnership convening five UN agencies and Mary Kay Inc., is today joining forces with the Commonwealth Businesswomen’s Network (CBWN) to empower and support underserved women entrepreneurs across the 54 countries of the Commonwealth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211027005291/en/
WEA is designed to maximize the development impact of women entrepreneurship in achieving the Sustainable Development Goals (SDGs) by creating an enabling ecosystem for women entrepreneurs that fosters growth, sustainability, and resilience. In June 2021, WEA joined the Generation Equality Forum in Paris and committed to empower five million women around the world by 2030 to accelerate progress for gender equality.
WEA recently announced the launch of a series of impactful initiatives and knowledge products, all shaped through a gender lens, as the joint outcome of the collaboration between the International Labour Organization (ILO), the International Trade Centre (ITC), UN Global Compact (UNGC), UN Development Programme (UNDP) and UN Women with the strategic support and funding of Mary Kay. WEA’s impact work includes digital capacity building tools and training; entrepreneurship research; and gender-responsive procurement (GRP) advocacy and training.
CBWN works with women in business by connecting governments and the private sector to encourage, enable and embed women’s economic empowerment and women in leadership. Originating in May 2021, the Commonwealth Women’s Entrepreneurship Accelerator (CWEA) is a strategic multi-stakeholder partnership from the CBWN, the Global Entrepreneurship Network UK (GEN UK) and Oxentia. It is a direct response to three developments: the agreement by all Commonwealth Heads of Government in London in 2018 “to work towards an increase in the number and enhancement of the success rate of women-owned businesses, break down gender barriers in all sectors, and increase opportunities for women to trade internationally”; the recognition by the G20 in 2020 that “there is a missed opportunity – to tackle the gap that needs immediate action, which is the representation of women in emerging fields”; and the UN Global Acceleration Plan to advance gender equality by 2026 and its Action Coalitions on Economic Justice and Rights and Technology and Innovation launched in 2021.
The new partnership with CBWN in support of CWEA further solidifies WEA’s geographic scope of action across the 54 Commonwealth diverse country members in Africa, Asia, the Americas, Europe, and the Pacific, with 32 countries classified as “small states.” Small states are especially vulnerable to climate change and developmental challenges including gender inequalities.
Beyond scaling WEA and CBWN’s foundational areas of work, the partnership will also significantly focus on policy and advocacy to advance systemic change engaging Commonwealth member states and leveraging its networks of organizations and key stakeholders in support of women in business or aspiring women entrepreneurs in and across the Commonwealth.
“We know that multi-stakeholder partnerships and collective engagement is crucial to drive the change that women entrepreneurs need across sectors around the world,” said Deborah Gibbins, Chief Operating Officer of Mary Kay Inc. “WEA is thrilled to join forces with the Commonwealth Businesswomen’s Network and the Commonwealth Women’s Entrepreneurship Accelerator. Our collaboration will focus on augmenting, amplifying and accelerating impact. We’re more powerful together, and I look forward to our collective action journey in support of the SDGs.”
“The Commonwealth Businesswomen’s Network is delighted to partner with the United Nations Women’s Entrepreneurship Accelerator in this landmark initiative so we can unlock and unleash the power and potential for more women of diverse backgrounds,” said Freda Miriklis, Chair, Commonwealth Businesswomen’s Network. “Through this partnership, we’ll be able to more quickly harness our collective assets - for women, their communities and every girl that can and will be inspired by their stories.”
To learn more about the Women’s Entrepreneurship Accelerator, visit we-accelerate.com .
About the Women’s Entrepreneurship Accelerator
The Women’s Entrepreneurship Accelerator (WEA) is a multi-partnership initiative on women’s entrepreneurship convening 5 UN agencies, International Labour Organization (ILO), International Trade Centre (ITC), UN Global Compact (UNGC), UN Development Programme (UNDP), UN Women and Mary Kay Inc. to empower 5 million women entrepreneurs by 2030.
The ultimate goal of the initiative is to maximize the development impact of women entrepreneurship in achieving Sustainable Development Goals (SDGs) by creating an enabling ecosystem for women entrepreneurs around the world. The Accelerator exemplifies the transformational power of a multi-partnership of unique magnitude to harness the potential of women entrepreneurs.
Learn more at we-accelerate . Follow us: Twitter (@We_Accelerator ), Instagram (@we_accelerator ), Facebook (@womensentrepreneurshipaccelerator ), LinkedIn (@womensentrepreneurshipaccelerator )
About the Commonwealth Businesswomen’s Network
The Commonwealth Businesswomen’s Network (CBWN) works with women in business by connecting Governments and the private sector to encourage, enable and embed women’s economic empowerment. This is achieved through delivering activities, initiatives, products, and services focused on trade, talent, and training. It is the only accredited organisation focused on women’s economic empowerment and directly recognized by 54 governments across six continents. Learn more at www.cbwn.org
About the Commonwealth Women’s Entrepreneurship Accelerator
The Commonwealth Women’s Entrepreneurship Accelerator is a strategic multi stakeholder partnership on women’s entrepreneurship established as an outcome of the inaugural Commonwealth Women’s Entrepreneurship Summit (CWES) in May 2021, the first global event to focus on women in emerging tech sectors. CWES was convened by the Commonwealth Businesswomen’s Network; the Global Entrepreneurship Network; the UK Government (Women in Innovation Network, a programme of Innovation UK); and Africa’s largest network of women entrepreneurs (AWEP: African Women’s Entrepreneurship Program). The Commonwealth Women’s Entrepreneurship Accelerator is a partnership between the Commonwealth Businesswomen’s Network, Global Entrepreneurship Network-UK and Oxentia. Learn more at www.thecwea.org
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 58 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements, and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at marykayglobal.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005291/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom